Skip to main content
Clinical Trials/NCT02569268
NCT02569268
Completed
Not Applicable

Early Vascular Disease Detection System for High Risk Patients in Beijing

Peking University Shougang Hospital0 sites2,000 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vascular Disease
Sponsor
Peking University Shougang Hospital
Enrollment
2000
Primary Endpoint
Number of vascular diseases-related death
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Arteriosclerotic vascular-related diseases have become a serious threat to human health. The prevention and reversal of vascular events has become an important direction of medicine. Early vascular disease detection system includes pulse wave velocity (PWV), carotid intima-media thickness (IMT) and coronary flow velocity reserve (CFVR), flow-mediated vasodilation (FMD), cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), insulin resistance index (HOMA-IR), hypersensitivity C- reactive protein (hs-CRP), plasma homocysteine (Hcy), B-type natriuretic peptide (BNP), uric acid (UA), and so on. However, there is no international and domestic comprehensive study on simple and practical evaluation system by jointing application of these evaluation indexes to detect vascular disease. Combined evaluation function can simultaneously detect and evaluate vascular abnormalities, make up a single indicator shortcoming in clinical applications from multiple levels of vascular structure and function. However, all indicators testing not only cause time consuming, but also increase the burden on patients, resulting unnecessary waste of medical resources. Thus, the present study was to select appropriate indicators and effective joint, and establish the rating system, using the vascular system to predict the incidence of terminal events, and compare this system with the previous scoring system such as FRS (Framingham Risk Score) pros and cons.

Detailed Description

This study aimed to establish vascular disease early detection system and scoring systems by comprehensive vascular disease risk factors and vascular function evaluation index. And prevention of vascular-related diseases, high-risk groups through positive lifestyle changes: such as lipid-lowering, smoking cessation, reversing early vascular lesions, to avoid end-stage vascular events. 1. Detection of vascular function indicators include: PWV, IMT, CFVR, FMD, CAVI, ABI, LDL-C, HOMA-IR, hs-CRP, Hcy, BNP, UA and so on. 2. Design the questionnaire: surveying the lifestyle, personal history, family history of the study population. 3. Follow-up:2 years of observation, recording the end time of vascular events, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease. 4. Statistics: Complex the factors of vascular disease, screen for an effective indicator to predict cardiovascular events, and based on the weight of the different factors, the establish the rating system, use the system to predict the incidence of vascular events terminal, and compare the system with the previous scoring system such as FRS (Framingham Risk Score).

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
December 2015
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hongyu Wang

Director and Professor of Vascular Medicine

Peking University Shougang Hospital

Eligibility Criteria

Inclusion Criteria

  • health subjects with or without history of vascular-related diseases; or
  • hypertension subjects; or
  • diabetes mellitus subjects; or
  • coronary artery disease; or
  • cerebrovascular disease;or
  • hyperlipidemia subjects.

Exclusion Criteria

  • severe infectious diseases and inflammatory diseases;
  • liver and kidney failure;
  • immunological diseases;
  • hematological system diseases。

Outcomes

Primary Outcomes

Number of vascular diseases-related death

Time Frame: Up to 1 year

Secondary Outcomes

  • Number of acute heart failure(Up to 1 year)
  • Number of acute coronary syndrome(Up to 1 year)
  • Number of peripheral arteriosclerosis occlusion(Up to 1 year)
  • Number of acute stroke(Up to 1 year)

Similar Trials